Matzim La Medication Summary
No separate FDA Medication Guide was found for this label. This summary is based on FDA/DailyMed prescribing information.
What is this medication?
Matzim LA is described in FDA/DailyMed prescribing information. No separate FDA Medication Guide was found for this label. This summary is based on FDA/DailyMed prescribing information.
What is this medication used for?
1 INDICATIONS AND USAGE Matzim LA (diltiazem hydrochloride) extended-release tablets are a nondihydropyridine calcium channel blocker indicated for: treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. It can be used alone or in combination with other antihypertensives. ( 1.1 ) improving exercise tolerance in patients with chronic stable angina. ( 1.2 ) 1.1 Hypertension Matzim LA (diltiazem hydrochloride) extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and.
What should I know before taking it?
Matzim LA (diltiazem hydrochloride) extended-release tablets are contraindicated in: Patients with sick sinus syndrome except in the presence of a functioning ventricular pacemaker. Patients with second- or third-degree AV block except in the presence of a functioning ventricular pacemaker. Patients with hypotension (less than 90 mm Hg systolic). Patients who have demonstrated hypersensitivity to the drug. Patients with acute myocardial infarction and pulmonary.
What important warnings are listed?
5 WARNINGS AND PRECAUTIONS Bradycardia, second- or third-degree AV block: Monitor heart rate and rhythm. ( 5.1 ) Heart failure: Monitor for signs and symptoms. ( 5.2 ) Increased liver enzymes and acute hepatic injury. ( 5.3 ) Severe skin reactions. ( 5.4 ) 5.1 Bradycardia or AV Block Matzim LA (diltiazem hydrochloride) extended-release tablets may cause abnormally slow heart rates or second- or third-degree AV block. Patients with sick sinus syndrome are at increased risk of bradycardia. Concomitant use of diltiazem with beta-blockers or digitalis may result in additive effects on cardiac conduction. A patient with Prinzmetal’s angina developed periods of asystole (2 to 5 seconds) after a.
How is this medication usually taken?
Take Matzim LA (diltiazem hydrochloride) extended-release tablets once a day at approximately the same time. Do not chew or crush the tablet. Extended-release tablets with 180 mg, 240 mg, 300 mg, 360 mg, or 420 mg diltiazem hydrochloride per tablet. Matzim LA (diltiazem hydrochloride) extended-release tablets, 180 mg are supplied as white, capsule-shaped tablets debossed with “180” on one side and “ 691”on the other. Matzim LA (diltiazem hydrochloride) extended-release tablets, 240 mg are supplied as white, capsule-shaped tablets debossed with “240” on one side and “ 692”on the other. Matzim LA (diltiazem hydrochloride) extended-release tablets, 300 mg are supplied as white, capsule-shaped.
What side effects are listed?
The following adverse reactions are described in greater detail, in other sections: Bradycardia and AV block [see Warnings and Precautions (5.1)] Heart failure [see Warnings and Precautions (5.2)] Acute hepatic injury [see Warnings and Precautions (5.3)] Severe skin reactions [see Warnings and Precautions (5.4)]
What interactions are listed?
7 DRUG INTERACTIONS Beta-blockers, digitalis, and other agents known to impair cardiac contractility and conduction may increase risk for hypotension, bradycardia, and heart failure. ( 7.1 ) CYP450 3A4: Diltiazem is both a substrate and inhibitor of CYP450 3A4. CYP450 3A4 substrates may require dosage adjustment. ( 7.2 ) 7.1 Agents Known to Impair Cardiac Contractility and Conduction Using other agents known to affect cardiac conduction or contractility with diltiazem may increase the risk of bradycardia, AV block, and heart failure [see Warnings and Precautions (5.1 , 5.2 ) ] . Ivabradine: Concurrent use of diltiazem increases exposure to ivabradine and may exacerbate bradycardia and.
Where can I find the official prescribing information?
Review the full prescribing information on DailyMed: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e8c8dd18-9d95-4068-9762-bec1eb1bc25c
⚠️ Disclaimer
This summary is for educational purposes only and is not medical advice. Always consult your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine. Read full medical disclaimer.